Use of Gabapentin for Postherpetic Neuralgia: Results of Two Randomized, Placebo-Controlled Studies

Brett R. Stacey, Robert L. Glanzman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Postherpetic neuralgia (PHN), which affects up to 70% of elderly persons with herpes zoster, can have debilitating effects, including physical and social disability and significant psychological distress. A variety of agents have been used, either singly or in combination, to control PHN, including topical and oral analgesics, antidepressants, and antiepileptic drugs (AEDs). However, PHN often proves refractory to these therapies. Objective: This article reviews available data on the use of the newer AED gabapentin for the control of PHN. Methods: A MEDLINE search was undertaken to identify all randomized, placebo-controlled trials on the use of gabapentin in PHN. The search terms were gabapentin and postherpetic neuralgia. Results: The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash. The studies employed multiple outcome measures, including visual analog and Likert scales for pain intensity, and quality-of-life and functional measures that included the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and the Profile of Mood States. At maximum target dosages of 1800 to 3600 mg/d, gabapentin produced significant reductions in mean daily pain scores compared with placebo on both visual analog (P <0.001) and Likert scales (P <0.01). Improvements were also seen on the SF-36 subscales for physical functioning, bodily pain, vitality, and mental health (P <0.01). Conclusion: Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic PHN.

Original languageEnglish (US)
Pages (from-to)2597-2608
Number of pages12
JournalClinical Therapeutics
Volume25
Issue number10
DOIs
StatePublished - 2003

Fingerprint

Postherpetic Neuralgia
Placebos
Herpes Zoster
Pain
Anticonvulsants
Quality of Life
Outcome Assessment (Health Care)
gabapentin
Drug and Narcotic Control
Pain Measurement
Exanthema
Health Surveys
MEDLINE
Antidepressive Agents
Analgesics
Mental Health
Randomized Controlled Trials
Psychology

Keywords

  • Gabapentin
  • Herpes zoster
  • Postherpetic neuralgia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Use of Gabapentin for Postherpetic Neuralgia : Results of Two Randomized, Placebo-Controlled Studies. / Stacey, Brett R.; Glanzman, Robert L.

In: Clinical Therapeutics, Vol. 25, No. 10, 2003, p. 2597-2608.

Research output: Contribution to journalArticle

Stacey, Brett R. ; Glanzman, Robert L. / Use of Gabapentin for Postherpetic Neuralgia : Results of Two Randomized, Placebo-Controlled Studies. In: Clinical Therapeutics. 2003 ; Vol. 25, No. 10. pp. 2597-2608.
@article{c1279bfb766f443cbbb36978bc744d29,
title = "Use of Gabapentin for Postherpetic Neuralgia: Results of Two Randomized, Placebo-Controlled Studies",
abstract = "Background: Postherpetic neuralgia (PHN), which affects up to 70{\%} of elderly persons with herpes zoster, can have debilitating effects, including physical and social disability and significant psychological distress. A variety of agents have been used, either singly or in combination, to control PHN, including topical and oral analgesics, antidepressants, and antiepileptic drugs (AEDs). However, PHN often proves refractory to these therapies. Objective: This article reviews available data on the use of the newer AED gabapentin for the control of PHN. Methods: A MEDLINE search was undertaken to identify all randomized, placebo-controlled trials on the use of gabapentin in PHN. The search terms were gabapentin and postherpetic neuralgia. Results: The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash. The studies employed multiple outcome measures, including visual analog and Likert scales for pain intensity, and quality-of-life and functional measures that included the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and the Profile of Mood States. At maximum target dosages of 1800 to 3600 mg/d, gabapentin produced significant reductions in mean daily pain scores compared with placebo on both visual analog (P <0.001) and Likert scales (P <0.01). Improvements were also seen on the SF-36 subscales for physical functioning, bodily pain, vitality, and mental health (P <0.01). Conclusion: Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic PHN.",
keywords = "Gabapentin, Herpes zoster, Postherpetic neuralgia",
author = "Stacey, {Brett R.} and Glanzman, {Robert L.}",
year = "2003",
doi = "10.1016/S0149-2918(03)80320-X",
language = "English (US)",
volume = "25",
pages = "2597--2608",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "10",

}

TY - JOUR

T1 - Use of Gabapentin for Postherpetic Neuralgia

T2 - Results of Two Randomized, Placebo-Controlled Studies

AU - Stacey, Brett R.

AU - Glanzman, Robert L.

PY - 2003

Y1 - 2003

N2 - Background: Postherpetic neuralgia (PHN), which affects up to 70% of elderly persons with herpes zoster, can have debilitating effects, including physical and social disability and significant psychological distress. A variety of agents have been used, either singly or in combination, to control PHN, including topical and oral analgesics, antidepressants, and antiepileptic drugs (AEDs). However, PHN often proves refractory to these therapies. Objective: This article reviews available data on the use of the newer AED gabapentin for the control of PHN. Methods: A MEDLINE search was undertaken to identify all randomized, placebo-controlled trials on the use of gabapentin in PHN. The search terms were gabapentin and postherpetic neuralgia. Results: The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash. The studies employed multiple outcome measures, including visual analog and Likert scales for pain intensity, and quality-of-life and functional measures that included the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and the Profile of Mood States. At maximum target dosages of 1800 to 3600 mg/d, gabapentin produced significant reductions in mean daily pain scores compared with placebo on both visual analog (P <0.001) and Likert scales (P <0.01). Improvements were also seen on the SF-36 subscales for physical functioning, bodily pain, vitality, and mental health (P <0.01). Conclusion: Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic PHN.

AB - Background: Postherpetic neuralgia (PHN), which affects up to 70% of elderly persons with herpes zoster, can have debilitating effects, including physical and social disability and significant psychological distress. A variety of agents have been used, either singly or in combination, to control PHN, including topical and oral analgesics, antidepressants, and antiepileptic drugs (AEDs). However, PHN often proves refractory to these therapies. Objective: This article reviews available data on the use of the newer AED gabapentin for the control of PHN. Methods: A MEDLINE search was undertaken to identify all randomized, placebo-controlled trials on the use of gabapentin in PHN. The search terms were gabapentin and postherpetic neuralgia. Results: The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash. The studies employed multiple outcome measures, including visual analog and Likert scales for pain intensity, and quality-of-life and functional measures that included the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and the Profile of Mood States. At maximum target dosages of 1800 to 3600 mg/d, gabapentin produced significant reductions in mean daily pain scores compared with placebo on both visual analog (P <0.001) and Likert scales (P <0.01). Improvements were also seen on the SF-36 subscales for physical functioning, bodily pain, vitality, and mental health (P <0.01). Conclusion: Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic PHN.

KW - Gabapentin

KW - Herpes zoster

KW - Postherpetic neuralgia

UR - http://www.scopus.com/inward/record.url?scp=0242593770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242593770&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(03)80320-X

DO - 10.1016/S0149-2918(03)80320-X

M3 - Article

C2 - 14667960

AN - SCOPUS:0242593770

VL - 25

SP - 2597

EP - 2608

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 10

ER -